{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:31:45Z","timestamp":1768444305902,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013700","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000}}],"reference-count":166,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013700.pub2","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T10:49:45Z","timestamp":1637923785000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis"],"prefix":"10.1002","volume":"2021","author":[{"given":"Martin A","family":"Walter","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Diagnostic Department; University Hospitals Geneva (HUG); Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Nesti","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery and Medicine; Bern University Hospital, University of Bern; Bern Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Spanjol","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Diagnostic Department; University Hospitals Geneva (HUG); Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Koll\u00e1r","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; Bern University Hospital, University of Bern; Bern Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"B\u00fctikofer","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Bern, University of Bern; Bern Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoria L","family":"Gloy","sequence":"additional","affiliation":[{"name":"Department of Clinical Research; University Hospital Basel and University of Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca A","family":"Dumont","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Diagnostic Department; University Hospitals Geneva (HUG); Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian A","family":"Seiler","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery and Medicine; Bern University Hospital, University of Bern; Bern Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel R","family":"Christ","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism; Basel University Hospital, University of Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Radojewski","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Diagnostic Department; University Hospitals Geneva (HUG); Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Briel","sequence":"additional","affiliation":[{"name":"Department of Clinical Research; University Hospital Basel and University of Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reto M","family":"Kaderli","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery and Medicine; Bern University Hospital, University of Bern; Bern Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"key":"10.1002\/14651858.CD013700.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/MPA.0b013e3182433b9f","article-title":"Impact of prior somatostatin analog use on PFS in the phase III radiant-2 trial of everolimus + octreotide lar vs placebo + octreotide lar in patients with advanced neuroendocrine tumors","volume":"41","author":"Anthony","year":"2012","journal-title":"Pancreas"},{"issue":"9808","key":"10.1002\/14651858.CD013700.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/MPA.0000000000000289","article-title":"Efficacy of octreotide long-acting repeatable (OCT) from the phase III RADIANT-2 study in patients with advanced neuroendocrine tumors (NET): A post-hoc analysis of the placebo (PBO) arm with updated survival data","volume":"44","author":"Strosberg","year":"2015","journal-title":"Pancreas"},{"issue":"8","key":"10.1002\/14651858.CD013700.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clinical Gastroenterolology and Hepatolology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/MPA.0000000000001516","article-title":"Randomized phase II trial of pazopanib versus placebo in patients (Pts) with progressive carcinoid tumors (CARC) (Alliance A021202)","volume":"49","author":"Bergsland","year":"2020","journal-title":"Pancreas"},{"issue":"15_suppl","key":"10.1002\/14651858.CD013700.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1200\/JCO.2019.37.15-suppl.4005","article-title":"Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202)","volume":"37","author":"Bergsland","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1016\/S0959-8049(16)31286-2","article-title":"Relative risk analysis of safety profile of lanreotide autogel\/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumours","volume":"51","author":"Phan","year":"2015","journal-title":"European Journal of Cancer"},{"issue":"15 SUPPL. 1","key":"10.1002\/14651858.CD013700.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"e15181","DOI":"10.1200\/jco.2015.33.15_suppl.e15181","article-title":"Relative risk of adverse events with lanreotide depot\/autogel (LAN) vs. Placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs)","volume":"33","author":"Phan","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"4 suppl","key":"10.1002\/14651858.CD013700.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/jco.2016.34.4_suppl.434","article-title":"Tumor response in the CLARINET study of lanreotide depot vs placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","volume":"34","author":"Phan","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0011|cit11","first-page":"75","article-title":"Health-related quality of life in CLARINET, a phase III trial of lanreotide autogel 120 mg in patients with non-functioning entero-pancreatic neuroendocrine tumour: Analytical challenges and statistical solutions","volume":"24","author":"Regnault","year":"2015","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0012|cit12","first-page":"357","article-title":"Quality of life (QoL) with lanreotide autogel\/depot (LAN) vs. placebo in patients with enteropancreatic neuroendocrine tumors: results from the CLARINET core study","volume":"44","author":"Ruszniewski","journal-title":"2015"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0013|cit13","first-page":"486","article-title":"Multivariate analysis of progression-free survival in the CLARINET study of lanreotide autogel\/depot vs placebo identifies prognostic factors in neuroendocrine tumors","volume":"Conference: 8th","author":"Wolin","year":"2016","journal-title":"Pancreas"},{"issue":"15_suppl","key":"10.1002\/14651858.CD013700.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"e15180","DOI":"10.1200\/jco.2015.33.15_suppl.e15180","article-title":"Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot\/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs)","volume":"33","author":"Wolin","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013700.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1634\/theoncologist.2012-0263","article-title":"Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study","volume":"18","author":"Castellano","year":"2013","journal-title":"Oncologist"},{"issue":"9808","key":"10.1002\/14651858.CD013700.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"15_suppl","key":"10.1002\/14651858.CD013700.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"e15177","DOI":"10.1200\/jco.2015.33.15_suppl.e15177","article-title":"Lanreotide depot\/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged > 65 vs. >65 years: subgroup analyses from the CLARINET study","volume":"33","author":"Dasari","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/MPA.0000000000001516","article-title":"Improvement in carcinoid syndrome-related symptoms with telotristat ethyl in patients with 2 or less bowel movements per day","volume":"49","author":"Di Gialleonardo","year":"2020","journal-title":"Pancreas"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocrine-related Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013700.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s00268-017-4324-9","article-title":"Radioembolization versus bland embolization for hepatic metastases from small intestinal neuroendocrine tumors: Short-term results of a randomized clinical trial","volume":"42","author":"Elf","year":"2018","journal-title":"World Journal of Surgery"},{"issue":"14","key":"10.1002\/14651858.CD013700.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","article-title":"Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group","volume":"21","author":"Faiss","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0023|cit23","first-page":"19","article-title":"Safety and efficacy of lanreotide depot vs. placebo in neuroendocrine tumor patients with a history of carcinoid syndrome and prior octreotide therapy","volume":"22","author":"Anselmo","year":"2016","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0024|cit24","first-page":"475","article-title":"Efficacy and safety of lanreotide depot vs placebo in patients with neuroendocrine tumor and a history of carcinoid syndrome and prior octreotide therapy","volume":"45","author":"Fisher","journal-title":"2016"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S1007","DOI":"10.14309\/00000434-201510001-02424","article-title":"Safety and efficacy of lanreotide depot versus placebo in neuroendocrine tumor patients with a history of carcinoid syndrome and prior octreotide therapy","volume":"110","author":"Fisher","year":"2015","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0026|cit26","first-page":"352","article-title":"Lanreotide depot\/autogel for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs) previously responsive to octreotide: subanalysis of patient-reported symptoms from the phase 3 elect study","volume":"47","author":"Pommier","year":"2018","journal-title":"Pancreas"},{"issue":"9","key":"10.1002\/14651858.CD013700.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (elect): A randomized, double-blind, placebo-controlled trial","volume":"22","author":"Vinik","year":"2016","journal-title":"Endocrine Practice"},{"issue":"10","key":"10.1002\/14651858.CD013700.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jjco\/hys123","article-title":"Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial","volume":"42","author":"Ito","year":"2012","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2796.1995.tb01175.x","article-title":"Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial","volume":"237","author":"Jacobsen","year":"1995","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours","volume":"90","author":"K\u00f6lby","year":"2003","journal-title":"British Journal of Surgery"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0032|cit32","first-page":"477","article-title":"Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (alliance)","volume":"45","author":"Kulke","year":"2016","journal-title":"Pancreas"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/annonc\/mdx078","article-title":"A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial","volume":"28","author":"Kulke","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0034|cit34","first-page":"337","article-title":"Time to sustained improvement in bowel movement frequency with telotristat ethyl: Analysis of the phase 3 telestar study","volume":"47","author":"Dillon","year":"2018","journal-title":"Pancreas"},{"issue":"1","key":"10.1002\/14651858.CD013700.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/MPA.0000000000000997","article-title":"Weight change associated with telotristat ethyl in the treatment of carcinoid syndrome","volume":"47","author":"Weickert","year":"2018","journal-title":"Pancreas"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0037|cit37","first-page":"1033","article-title":"A randomized, prospective trial of postoperative somatostatin analogue in patients with neuroendocrine tumors of the pancreas","volume":"112","author":"Lange","year":"1992","journal-title":"Surgery"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"S774","DOI":"10.1016\/j.annonc.2020.08.1376","article-title":"Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial","volume":"31","author":"Lepage","year":"2020","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013700.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00259-019-04530-1","article-title":"Dose escalation of an Evans blue-modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors","volume":"47","author":"Liu","year":"2020","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"2","key":"10.1002\/14651858.CD013700.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MPA.0000000000000262","article-title":"Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial","volume":"44","author":"Lombard-Bohas","year":"2015","journal-title":"Pancreas"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013700.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000336941","article-title":"Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study","volume":"96","author":"Maire","year":"2012","journal-title":"Neuroendocrinology"},{"issue":"5","key":"10.1002\/14651858.CD013700.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"902-11","DOI":"10.1016\/j.ejca.2013.12.011","article-title":"Capecitabine and streptozocin \u00b1 cisplatin in advanced gastroenteropancreatic neuroendocrine tumours","volume":"50","author":"Meyer","year":"2014","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0044|cit44","first-page":"136","article-title":"Capecitabine and streptozocin \u00b1 cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial","volume":"27","author":"Meyer","year":"2016","journal-title":"Annals of Oncology"},{"issue":"21","key":"10.1002\/14651858.CD013700.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma","volume":"303","author":"Moertel","year":"1980","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013700.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013700.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O'Toole","year":"2000","journal-title":"Cancer"},{"issue":"10","key":"10.1002\/14651858.CD013700.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/0277-5379(89)90107-7","article-title":"Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon","volume":"25","author":"Oberg","year":"1989","journal-title":"European Journal of Cancer and Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013700.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdx193","article-title":"Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study","volume":"28","author":"Pavel","year":"2017","journal-title":"Annals of Oncology"},{"issue":"9808","key":"10.1002\/14651858.CD013700.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0051|cit51","first-page":"350","article-title":"Correlation of progression-free survival (PFS) with early response of biomarkers chromogranin a (CGA) and 5-hhydroxyindoleacetic acid (5-HIAA) levels in patients with advanced neuroendocrine tumors: phase III radiant-2 study results","volume":"41","year":"2012","journal-title":"Pancreas"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/MPA.0b013e31820e7892","article-title":"Radiant-2: A phase III trial of everolimus + octreotide lar in patients with advanced neuroendocrine tumors (NET)","volume":"40","author":"Yao","year":"2011","journal-title":"Pancreas"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocrine-related Cancer"},{"issue":"15_suppl","key":"10.1002\/14651858.CD013700.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1200\/JCO.2020.38.15_suppl.4608","article-title":"Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)-First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS)","volume":"38","author":"Pavlakis","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"15_suppl","key":"10.1002\/14651858.CD013700.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"e15177","DOI":"10.1200\/jco.2015.33.15_suppl.e15177","article-title":"Lanreotide depot\/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged <65 vs. >65 years: subgroup analyses from the CLARINET study","volume":"33","author":"Dasari","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0057|cit57","first-page":"36","article-title":"Effects of lanreotide autogel\/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: subgroup analyses from the CLARINET study","volume":"33","author":"Phan","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1200\/jco.2015.33.3_suppl.233","article-title":"Effects of lanreotide autogel\/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): a subgroup analysis from the CLARINET study","volume":"33","author":"Phan","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"viii472","DOI":"10.1093\/annonc\/mdy293.012","article-title":"Post-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide(LAN) or placebo (PBO)","volume":"29","author":"Pusceddu","year":"2018","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013700.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","author":"Faivre","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1359-6349(09)71223-6","article-title":"Sunitinib (SU) vs placebo for treatment of progressive, well-differentiated pancreatic islet cell tumours: results of a phase III, randomised, double-blind trial","volume":"7","author":"Raoul","year":"2009","journal-title":"European Journal of Cancer, supplement"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0065|cit65","first-page":"84","article-title":"Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (PNET): final overall survival (OS) results from a phase III randomized study including adjustment for crossover","volume":"103","author":"Raymond","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"15 SUPPL. 1","key":"10.1002\/14651858.CD013700.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/jco.2011.29.15_suppl.4008","article-title":"Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advance unresectable pancreatic neuroendocrine tumors (NET)","volume":"29","author":"Raymond","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1016\/S0959-8049(11)71880-9","article-title":"Updated overall survival data from a phase III study of sunitinib vs. placebo in patients with advanced, unresectable pancreatic neuroendocrine tumour (NET)","volume":"47","author":"Valle","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11523-016-0462-5","article-title":"Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from an international phase III trial","volume":"11","author":"Vinik","year":"2016","journal-title":"Targeted Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0069|cit69","first-page":"350","article-title":"Progression-free survival (PFS) by blinded independent central review (BICR) and updated overall survival (OS) of sunitinib versus placebo for patients with progressive, unresectable, well differentiated pancreatic neuroendocrine tumor (NET)","volume":"41","author":"Vinik","year":"2012","journal-title":"Pancreas"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0071|cit71","first-page":"41","article-title":"Impact of baseline Ki-67 index and other baseline characteristics on outcome in a study of sunitinib (SU) for the treatment of advanced, progressive pancreatic neuroendocrine tumor (NET)","volume":"94","author":"Raymond","year":"2011","journal-title":"Neuroendocrinology"},{"issue":"28","key":"10.1002\/14651858.CD013700.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013700.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000499469","article-title":"Health-related quality of life for long-acting octreotide versus placebo in patients with metastatic midgut neuroendocrine tumors in the phase 3 PROMID Trial","volume":"109","author":"Rinke","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1002\/14651858.CD013700.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"25","key":"10.1002\/14651858.CD013700.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.3748\/wjg.v12.i25.4026","article-title":"A pilot randomized control study to evaluate endoscopic resection using a ligation device for rectal carcinoid tumors","volume":"12","author":"Sakata","year":"2006","journal-title":"World Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD013700.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"766-71","DOI":"10.1634\/theoncologist.2017-0144","article-title":"Phase II study of BEZ235 versus everolimus in patients with mammalian target of rapamycin inhibitor-na\u00efve advanced pancreatic neuroendocrine tumors","volume":"23","author":"Salazar","year":"2018","journal-title":"Oncologist"},{"issue":"5","key":"10.1002\/14651858.CD013700.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/gut.42.5.628","article-title":"Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea","volume":"42","author":"Saslow","year":"1998","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000477585","article-title":"Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary","volume":"106","author":"Singh","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"10022","key":"10.1002\/14651858.CD013700.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0080|cit80","first-page":"488","article-title":"Randomized embolization trial for neuroendocrine tumors (RETNET): first safety report","volume":"49","author":"Soulen","year":"2020","journal-title":"Pancreas"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.14309\/00000434-201110002-00143","article-title":"Prognostic value of chromogranin a and neuron-specific enolase in patients with advanced pancreatic neuroendocrine tumors (pNET): phase III RADIANT-3 study results 2011 ACG presidential poster","volume":"106","author":"Strosberg","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013700.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/MPA.0000000000000997","article-title":"QOL improvements in netter-1 phase III trial in patients with progressive midgut neuroendocrine tumors","volume":"47","author":"Strosberg","year":"2018","journal-title":"Pancreas"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000484263","article-title":"NETTER-1 phase III trial: Recent findings on quality of life in patients with midgut neuroendocrine tumors","volume":"105","author":"Strosberg","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1002\/14651858.CD013700.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/MPA.0000000000001516","article-title":"Impact of baseline liver tumor burden, alkaline phosphatase (ALP) elevation, and target size lesion on therapeutic effect of 177LU-DOTATATE treatment: Analysis of progression free survival, and safety in NETTER-1 study","volume":"49","author":"Strosberg","year":"2020","journal-title":"Pancreas"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000487699","article-title":"A randomized controlled study comparing treatment of gastro-entero-pancreatic neuroendocrine tumors (GEPNET) with 177Lu-Dotatate alone and in combination with capecitabine","volume":"106","author":"Van Der Zwan","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0089|cit89","first-page":"338","article-title":"An exploratory patientcentricanalysis of the elect trial: A phase 3 study of efficacy and safety of lanreotide autogel\/depot (LAN) treatment for patients with carcinoid syndrome (CS)","volume":"Conference: 10t","author":"Duchateau","year":"2018","journal-title":"Pancreas"},{"issue":"9","key":"10.1002\/14651858.CD013700.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (elect): A randomized, double-blind, placebo-controlled trial","volume":"22","author":"Vinik","year":"2016","journal-title":"Endocrine Practice"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/MPA.0000000000000997","article-title":"Change in patient-reported symptom control in patients with neuroendocrine tumors treated with lanreotide depot","volume":"47","author":"Wolin","year":"2018","journal-title":"Pancreas"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Design, Development and Therapy"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"15_suppl","key":"10.1002\/14651858.CD013700.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"e15182","DOI":"10.1200\/jco.2015.33.15_suppl.e15182","article-title":"Lanreotide depot\/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study","volume":"33","author":"Wolin","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD013700.pub2-BIB0095|cit95","first-page":"e15182","article-title":"Lanreotide depot\/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study","volume":"33","author":"Wolin","year":"2016","journal-title":"Pancreas"},{"issue":"11","key":"10.1002\/14651858.CD013700.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"v911","DOI":"10.1093\/annonc\/mdz394.073","article-title":"Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): results from the randomized phase III study (SANET-ep)","volume":"30","author":"Xu","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"S770","DOI":"10.1016\/j.annonc.2020.08.1369","article-title":"Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): a randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)","volume":"31","author":"Xu","year":"2020","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013700.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013700.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b","volume":"26","author":"Yao","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD013700.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"10624","DOI":"10.1200\/jco.2011.29.15_suppl.10624","article-title":"Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): phase III RADIANT-3 study results","volume":"29","author":"De Vries","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"32","key":"10.1002\/14651858.CD013700.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","article-title":"Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: Overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study","volume":"34","author":"Yao","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013700.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1470-2045(17)30471-0","article-title":"Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Pavel","year":"2017","journal-title":"Lancet Oncology"},{"issue":"10022","key":"10.1002\/14651858.CD013700.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"15","key":"10.1002\/14651858.CD013700.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.2016.70.4072","article-title":"Phase III prospective randomized comparison trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518","volume":"35","author":"Yao","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"10022","key":"10.1002\/14651858.CD013700.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2147\/OTT.S182259","article-title":"Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in east asian patients: A subgroup analysis of the RADIANT-4 study","volume":"12","author":"Yao","year":"2019","journal-title":"OncoTargets and Therapy"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD013700.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/cncr.32750","article-title":"Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study","volume":"126 Suppl 9","author":"Zhang","year":"2020","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/jco.2014.32.15_suppl.4107","article-title":"Progression-free survival (PFS) with lanreotide autogel\/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study","volume":"32","author":"Caplin","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0111|cit111","first-page":"151","article-title":"Systemic markers of inflammation in neuroendocrine tumors (NETs) and outcomes with everolimus: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials","volume":"Conference: 15t","author":"Chan","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"v150","DOI":"10.1093\/annonc\/mdx368.023","article-title":"Final analysis of time to subsequent disease progression\/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel\/depot 120mg in the CLARINET open-label extension","volume":"28","author":"Cwikla","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0113|cit113","first-page":"211","article-title":"Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors (NETs): A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials","volume":"Conference: 15t","author":"Fazio","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1002\/14651858.CD013700.pub2-BIB0114|cit114","first-page":"34","article-title":"Delayed gastric emptying following pancreatoduodenectomy: a Roux-en-Y gastrojejunostomy vs Billroth II gastrojejunostomy randomized study","volume":"111","author":"Herrera Cabez\u00f3n","year":"2019","journal-title":"Revista espanola de enfermedades digestivas"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0115|cit115","first-page":"341","article-title":"Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed telestar extension period","volume":"47","author":"Kulke","year":"2018","journal-title":"Pancreas"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/jco.2011.29.4_suppl.289","article-title":"Everolimus versus placebo in Japanese patients with advanced pancreatic neuroendocrine tumors (pNET): japanese subgroup analysis of RADIANT-3","volume":"29","author":"Ito","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013700.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/annonc\/mdz219","article-title":"Erratum: a randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial","volume":"30","author":"Kulke","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0118|cit118","first-page":"345","article-title":"Integrated safety analysis of telotristat ethyl in patients with carcinoid heart disease","volume":"47","author":"Kulke","year":"2018","journal-title":"Pancreas"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"vi136-48","DOI":"10.1093\/annonc\/mdw369.31","article-title":"Capecitabine and streptozocin \u00b1 cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial","volume":"27","author":"Meyer","year":"2016","journal-title":"Annals of Oncology"},{"issue":"supplement 1","key":"10.1002\/14651858.CD013700.pub2-BIB0120|cit120","first-page":"60","article-title":"A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with GEP-NETs in a phase II clinical trial","volume":"61","author":"Miller","year":"2020","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"xi15","DOI":"10.1016\/S0923-7534(20)31952-9","article-title":"Phase III trial of everolimus in advanced pancreatic neuroendocrine tumors (RADIANT-3): overall population and Japanese subgroup analysis","volume":"23","author":"Ito","year":"2012","journal-title":"Annals of Oncology"},{"issue":"15 SUPPL. 1","key":"10.1002\/14651858.CD013700.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/jco.2015.33.15_suppl.4091","article-title":"Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias","volume":"33","author":"Pavel","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0123|cit123","first-page":"263","article-title":"Disease control in progressive pancreatic and intestinal neuroendocrine tumours with combined treatment with lanreotide Autogel and temozolomide: The SONNET study","volume":"41","author":"Pavel","year":"2018","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0124|cit124","first-page":"202","article-title":"Disease control in progressive pancreatic and intestinal neuroendocrine tumors by combined treatment with lanreotide autogel and temozolomide: The sonnet study","volume":"106","author":"Pavel","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0125|cit125","first-page":"207","article-title":"Long-term efficacy and safety with lanreotide autogel\/depot (LAN) from CLARINET and Open-Label Extension (OLE) studies","volume":"105","author":"Pavel","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"SONDERHEFT 1","key":"10.1002\/14651858.CD013700.pub2-BIB0126|cit126","first-page":"9","article-title":"Update on antitumor acitivity of lanreotide autogel (LAN) treatment for enteropancreatic neuroendocrine tumours (NET): the CLARINET open-label extension (OLE) study","volume":"8","author":"Raderer","year":"2015","journal-title":"Austrian journal of clinical endocrinology and metabolism"},{"issue":"15 SUPPL. 1","key":"10.1002\/14651858.CD013700.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/jco.2015.33.15_suppl.4102","article-title":"Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET)","volume":"33","author":"Salazar","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/jso.24873","article-title":"Pancreaticojejunostomy: Does the technique matter? A randomized trial","volume":"117","author":"Singh","year":"2018","journal-title":"Journal of Surgical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013700.pub2-BIB0129|cit129","first-page":"385","article-title":"Effect of open-label everolimus in patients with advanced neuroendocrine tumors after disease progression on somatostatin analog: A RADIANT-2 analysis","volume":"42","author":"Wolin","year":"2013","journal-title":"Pancreas"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0130|cit130","first-page":"358-9","article-title":"Final progression-free survival analyses for lanreotide autogel\/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors: the CLARINET extension study","volume":"47","author":"Wolin","year":"2018","journal-title":"Pancreas"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0131|cit131","first-page":"1717","article-title":"Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in east asian patients: A subgroup analysis of the RADIANT-4 study","volume":"12","author":"Oh","year":"2015","journal-title":"OncoTargets and Therapy"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0132|cit132","unstructured":"Sandostatin LAR and axitinib versus placebo in patients with advanced well-differentiated non-pancreatic neuroendocrine carcinomas clinicaltrials.gov\/show\/NCT01744249"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0133|cit133","unstructured":"Efficacy and safety of everolimus and (streptozotocin- fluorouracil) given one upfront the other upon progression in advanced pancreatic neuroendocrine tumour clinicaltrials.gov\/show\/NCT02246127"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0134|cit134","unstructured":"Efficacy and safety of 177Lu-edotreotide PRRT in GEP-NET patients clinicaltrials.gov\/show\/NCT03049189"},{"issue":"5","key":"10.1002\/14651858.CD013700.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"10.1002\/14651858.CD013700.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","article-title":"BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network meta-analyses","volume":"19","author":"B\u00e9liveau","year":"2019","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9","key":"10.1002\/14651858.CD013700.pub2-BIB0138|cit138","first-page":"749","article-title":"An update on gastroenteropancreatic neuroendocrine tumors","volume":"28","author":"Cives","year":"2014","journal-title":"Oncology (Williston Park)"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1159\/000503721","article-title":"Neuroendocrine neoplasms of the small bowel and pancreas","volume":"110","author":"Clift","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"10","key":"10.1002\/14651858.CD013700.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/jso.25662","article-title":"Interaction of race and pathology for neuroendocrine tumors: epidemiology, natural history, or racial disparity?","volume":"120","author":"DePalo","year":"2019","journal-title":"Journal of Surgical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013700.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bpg.2013.01.006","article-title":"Epidemiology of gastroenteropancreatic neuroendocrine tumours","volume":"26","author":"Fraenkel","year":"2012","journal-title":"Best Practice & Research Clinical Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/ERC-13-0125","article-title":"Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature","volume":"21","author":"Fraenkel","year":"2014","journal-title":"Endocrine-related Cancer"},{"issue":"4","key":"10.1002\/14651858.CD013700.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0145|cit145","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"issue":"9","key":"10.1002\/14651858.CD013700.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1530\/ERC-17-0197","article-title":"Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms","volume":"24","author":"Imaoka","year":"2017","journal-title":"Endocrine-related Cancer"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0147|cit147","first-page":"16","volume-title":"WHO Classification of Tumours: Digestive System Tumours","author":"Klimstra","year":"2019"},{"issue":"4","key":"10.1002\/14651858.CD013700.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"issue":"1","key":"10.1002\/14651858.CD013700.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"issue":"1","key":"10.1002\/14651858.CD013700.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0151|cit151","unstructured":"National Cancer Institute Common terminology criteria for adverse events (CTCAE), version 4.03 evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"},{"issue":"2","key":"10.1002\/14651858.CD013700.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS Consensus Guidelines Update for the management of distant metastatic disease of intestinal, pancreatic, bronchial Neuroendocrine Neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1002\/14651858.CD013700.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/ije\/dym087","article-title":"Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials","volume":"36","author":"Pildal","year":"2008","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD013700.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)","volume":"61","author":"Ramage","year":"2012","journal-title":"Gut"},{"issue":"11","key":"10.1002\/14651858.CD013700.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1056\/NEJMx110017","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0157|cit157","unstructured":"R Foundation for Statistical Computing R: A Language and Environment for Statistical Computing R Core Team 2019"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0158|cit158","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"4","key":"10.1002\/14651858.CD013700.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"25","key":"10.1002\/14651858.CD013700.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD013700.pub2-BIB0162|cit162","unstructured":"R\u00fccker G Krahn U K\u00f6nig J Efthimiou O Davies A Papakonstantinou T Schwarzer G Netmeta: network meta-analysis using frequentist methods cran.r-project.org\/web\/packages\/netmeta\/netmeta.pdf"},{"issue":"3","key":"10.1002\/14651858.CD013700.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/annonc\/mdv562","article-title":"Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents","volume":"27","author":"Saad","year":"2016","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013700.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLOS One"},{"issue":"18","key":"10.1002\/14651858.CD013700.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013700.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamaoncol.2018.6720","article-title":"Therapeutic options for neuroendocrine tumors: a systematic review and network meta-analysis","volume":"5","author":"Kaderli","year":"2019","journal-title":"JAMA Oncology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T14:20:58Z","timestamp":1667053258000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013700.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":166,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013700.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]}}}